BCBrooke A. Conti

Brooke A. Conti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brooke A. Conti has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RTF2 and CLASPIN localize CHK1 to the replication fork to control S-phase progression

    by Cayla Broton, Catherine L. W. Miller, Penelope D. Ruiz, Nicolas J. Blobel, Yibing Yao, Brooke A. Conti, Ernst W. Schmid, Johannes C. Walter, Agata Smogorzewska

    The essential kinase ataxia telangiectasia and Rad3-related (ATR) monitors the replicative (S) phase of the cell cycle to ensure faithful propagation of genetic material. While much is known about the mechanisms governing ATR activity at replication forks, how its effector checkpoint kinase 1 (CHK1) is regulated to create a localized hub of CHK1 activity at sites of replication remains poorly understood. Here, we report that replication termination factor 2 (RTF2), an essential replisome-associated protein, is necessary for maintaining CHK1 signaling at replication forks. RTF2 interacts with CHK1 and functions alongside the core replicative helicase complex-interacting protein CLASPIN to tether CHK1 to sites of DNA replication, controlling replication rates and preventing premature mitotic entry. These findings uncover how RTF2 and CLASPIN poise CHK1 at replication forks to facilitate its activation by ATR, creating fork-localized CHK1 activity that fuels unperturbed S-phase progression and promotes genome stability by maintaining the intrinsic S-G 2 checkpoint.

  • Open Access

    N6-methyladenosine in DNA promotes genome stability

    by Brooke A Conti, Leo Novikov, Deyan Tong, Qing Xiang, Savon Vigil, Thomas J McLellan, Chuong Nguyen, Nancy De La Cruz, Reshma T Veettil, Prashant Pradhan, et al.

    DNA base lesions, such as incorporation of uracil into DNA or base mismatches, can be mutagenic and toxic to replicating cells. To discover factors in repair of genomic uracil, we performed a CRISPR knockout screen in the presence of floxuridine, a chemotherapeutic agent that incorporates uracil and fluorouracil into DNA. We identified known factors, such as uracil DNA N-glycosylase (UNG), and unknown factors, such as the N6-adenosine methyltransferase, METTL3, as required to overcome floxuridine-driven cytotoxicity. Visualized with immunofluorescence, the product of METTL3 activity, N6-methyladenosine, formed nuclear foci in cells treated with floxuridine. The observed N6-methyladenosine was embedded in DNA, called 6mA, and these results were confirmed using an orthogonal approach, liquid chromatography coupled to tandem mass spectrometry. METTL3 and 6mA were required for repair of lesions driven by additional base-damaging agents, including raltitrexed, gemcitabine, and hydroxyurea. Our results establish a role for METTL3 and 6mA in promoting genome stability in mammalian cells, especially in response to base damage.

  • Open Access

    N6-methyladenosine in DNA promotes genome stability

    by Brooke A Conti, Leo Novikov, Deyan Tong, Qing Xiang, Savon Vigil, Thomas J McLellan, Chuong Nguyen, Nancy De La Cruz, Reshma T Veettil, Prashant Pradhan, et al.

    DNA base lesions, such as incorporation of uracil into DNA or base mismatches, can be mutagenic and toxic to replicating cells. To discover factors in repair of genomic uracil, we performed a CRISPR knockout screen in the presence of floxuridine, a chemotherapeutic agent that incorporates uracil and fluoro-uracil into DNA. We identified known factors, such as uracil DNA N-glycosylase (UNG), and unknown factors, such as the N6-adenosine methyltransferase, METTL3, as required to overcome floxuridine-driven cytotoxicity. Visualized with immunofluorescence, the product of METTL3 activity, N6-methyladenosine, formed nuclear foci in cells treated with floxuridine. The observed N6-methyladenosine was embedded in DNA, called 6mA, and these results were confirmed using an orthogonal approach, liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). METTL3 and 6mA were required for repair of lesions driven by additional base damaging agents, including raltitrexed, gemcitabine, and hydroxyurea. Our results establish a role for METTL3 and 6mA in promoting genome stability in mammalian cells, especially in response to base damage.

  • Open Access

    N6-methyladenosine in DNA promotes genome stability

    by Brooke A. Conti, Leo Novikov, Deyan Tong, Qing Xiang, Savon Vigil, Thomas J. McLellan, Chuong Nguyen, Nancy De La Cruz, Reshma T. Veettil, Prashant Pradhan, et al.

    Summary: DNA base lesions, such as incorporation of uracil into DNA or base mismatches, can be mutagenic and toxic to replicating cells. To discover factors in repair of genomic uracil, we performed a CRISPR knockout screen in the presence of floxuridine, a chemotherapeutic agent that incorporates uracil and fluoro-uracil into DNA. We identified known factors, such as uracil DNA N-glycosylase (UNG), and unknown factors, such as the N6-adenosine methyltransferase, METTL3, as required to overcome floxuridine-driven cytotoxicity. Visualized with immunofluorescence, the product of METTL3 activity, N6-methyladenosine, formed nuclear foci in cells treated with floxuridine. The observed N6-methyladenosine was embedded in DNA, called 6mA, and these results were confirmed using an orthogonal approach, liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). METTL3 and 6mA were required for repair of lesions driven by additional base damaging agents, including raltitrexed, gemcitabine, and hydroxyurea. Our results establish a role for METTL3 and 6mA in promoting genome stability in mammalian cells, especially in response to base damage.

  • Open Access

    Supplementary Figures 1-9 from CAF-Secreted IGFBPs Regulate Breast Cancer Cell Anoikis

    by Kelsey J. Weigel, Ana Jakimenko, Brooke A. Conti, Sarah E. Chapman, William J. Kaliney, W. Matthew Leevy, Matthew M. Champion, Zachary T. Schafer

  • Open Access

    RTF2 controls replication repriming and ribonucleotide excision at the replisome

    by Brooke A. Conti, Penelope D. Ruiz, Cayla Broton, Nicolas J. Blobel, Molly C. Kottemann, Sunandini Sridhar, Francis P. Lach, Tom Wiley, Nanda K. Sasi, Thomas Carroll, et al.

    Genetic information is duplicated via the highly regulated process of DNA replication. The machinery coordinating this process, the replisome, encounters many challenges, including replication fork-stalling lesions that threaten the accurate and timely transmission of genetic information. Cells have multiple mechanisms to repair or bypass lesions that would otherwise compromise DNA replication 1,2 . We have previously shown that proteasome shuttle proteins, DNA Damage Inducible 1 and 2 (DDI1/2) function to regulate Replication Termination Factor 2 (RTF2) at the stalled replisome, allowing for replication fork stabilization and restart 3 . Here we show that RTF2 regulates replisome localization of RNase H2, a heterotrimeric enzyme responsible for removing RNA in the context of RNA-DNA heteroduplexes 4–6 . We show that during unperturbed DNA replication, RTF2, like RNase H2, is required to maintain normal replication fork speeds. However, persistent RTF2 and RNase H2 at stalled replication forks compromises the replication stress response, preventing efficient replication restart. Such restart is dependent on PRIM1, the primase component of DNA polymerase α-primase. Our data show a fundamental need for regulation of replication-coupled ribonucleotide incorporation during normal replication and the replication stress response that is achieved through RTF2. We also provide evidence for PRIM1 function in direct replication restart following replication stress in mammalian cells.


  • Suppression of non-homologous end joining does not rescue DNA repair defects in Fanconi anemia patient cells

    by Supawat Thongthip, Brooke A. Conti, Francis P. Lach, Agata Smogorzewska

    Severe cellular sensitivity and aberrant chromosomal rearrangements in response to DNA interstrand crosslink (ICL) inducing agents are hallmarks of Fanconi anemia (FA) deficient cells. These phenotypes have previously been ascribed to inappropriate activity of non-homologous end joining (NHEJ) rather than a direct consequence of DNA ICL repair defects. Here we used chemical inhibitors, RNAi, and Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas9 to inactivate various components of NHEJ in cells from FA patients. We show that suppression of DNA-PKcs, DNA Ligase IV, and 53BP1 is not capable of rescuing ICL-induced proliferation defects and only 53BP1 knockout partially suppresses the chromosomal abnormalities of FA patient cells.


  • Removal of RTF2 from Stalled Replisomes Promotes Maintenance of Genome Integrity

    by Molly C. Kottemann, Brooke A. Conti, Francis P. Lach, Agata Smogorzewska